ASXL1 was the most frequently mutated gene in the chronic (14%) and accelerated phase (40%) CML patients, whereas RUNX1 (20%) was the most common mutation in blast phase. Here, RUNX1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.